Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Eszopiclone and Lemborexant in People With Obstructive Sleep Apnoea (ELOSA)
NCT06928766Phase 2Recruiting
- Sponsor
- Flinders University
- Start
- Oct 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing Eszopiclone 3mg and lemborexant 10mg with Placebo (2 arms). Primary endpoint: Change in OSA severity up to 1 month. Started Oct 2025; status: recruiting.
02
Drugs
eszopiclonelemborexant
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT06928766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928766.